KRYS
Krystal Biotech, Inc.·Healthcare
259.00
0.259%(+0.67)
Market ClosedLast Updated: — ET
52W L: $122.8052W H: $298.30
KRYS NEWS
fool.com
3d ago
Could This Under-the-Radar Healthcare Stock Set You Up for Life?
Krystal Biotech has attractive prospects within its core market. The biotech could launch more products in the next few years.
247wallst.com
Mar 29
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
zacks.com
Mar 19
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
fool.com
Feb 22
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
Redmile Group bought 16,317 shares of Krystal Biotech; the estimated trade size was $3.43 million based on average closing prices in the fourth quarter. The quarter-end value of the Krystal Biotech position increased by $50.33 million, reflecting both trading and price movement effects.
zacks.com
Feb 18
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.
defenseworld.net
Feb 18
Krystal Biotech (NASDAQ:KRYS) Shares Gap Up Following Better-Than-Expected Earnings
Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) shares gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $276.45, but opened at $289.00. Krystal Biotech shares last traded at $285.45, with a volume of 212,409 shares. The company reported $1.70 earnings per
